Develops antibodies for obesity and cardiometabolic diseases.
Jun 2026Revenue $100K/yrExpenses $35.2M/yr
No trendCash runway ≈ 3.7 years from Jun 2026
Figures by year
When will iBio be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $100K and expenses $35.2M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Jun 2026 | $100K | $35.2M | −$35.1M |
| Jun 2025 | $400K | $19.0M | −$18.6M |
| Jun 2024 | $225K | $16.9M | −$16.6M |
| Jun 2023 | $0.00 | $29.3M | −$29.3M |
| Jun 2022 | $1.88M | $31.6M | −$29.7M |
| Jun 2021 | $2.37M | $33.5M | −$31.1M |
| Jun 2020 | $1.64M | $15.6M | −$14.0M |
| Jun 2019 | $2.02M | $17.8M | −$15.8M |
| Jun 2018 | $444K | $14.7M | −$14.2M |
| Jun 2017 | $394K | $14.7M | −$14.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.